DeepMed Research

Insel Gruppe AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Private

Established: 2016-01-01

Employees: 10K

Market Cap: -

Website: https://www.inselgruppe.ch

Clinical Trials

Predicting Outcomes in ICH Patients on Direct Factor Xa Inhibitors

Recruiting

Conditions: Intra Cerebral Hemorrhage

First Posted Date: 2024-04-25

Last Posted Date: 2024-04-25

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 200

Registration Number: NCT06383741

Locations: 🇨🇭
Insel Gruppe AG, Inselspital Bern, Bern, Switzerland

Conebeam CT-based Online Adaptive Radio-Therapy for Esophageal Cancer (ARTEC)

Recruiting

Conditions: Esophageal Cancer

First Posted Date: 2024-04-11

Last Posted Date: 2024-04-25

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 30

Registration Number: NCT06361043

Locations: 🇨🇭
Inselspital, University of Berne, Deparftment of Radio-Oncology, Berne, Switzerland

CT-guided Lung Biopsy Risk Optimization Method

Not Applicable

Not yet recruiting

Conditions: Biopsy, Needle
Risk Factors
Radiology, Interventional
Pneumothorax

Interventions: Procedure: Fluid application during ct-guided lung biopsy

First Posted Date: 2024-04-01

Last Posted Date: 2024-12-20

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 198

Registration Number: NCT06340178

Locations: 🇨🇭
Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 10, Bern, Switzerland

A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis

Phase 2

Recruiting

Conditions: Giant Cell Arteritis

Interventions: Drug: AzaFol
Drug: FDG

First Posted Date: 2024-03-28

Last Posted Date: 2025-02-13

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 70

Registration Number: NCT06335888

Locations: 🇨🇭
Department of Rheumatology and Immunology, University Hospital Bern, Inselspital, Bern, Switzerland

Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy

Recruiting

Conditions: Vaccine Immunity in CAR-T Cell Therapy Recipients

First Posted Date: 2024-03-27

Last Posted Date: 2024-03-27

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 80

Registration Number: NCT06333275

Locations: 🇨🇭
University Hospital Bern, Bern, Switzerland

Administration of Intranasal Midazolam for Anxiety in Palliative Care

Phase 2

Recruiting

Conditions: Anxiety
Acute Anxiety
Palliative Care

Interventions: Drug: Midazolam Nasal Spray 0.45 mg/spray
Drug: Placebo Nasal Spray 0 mg/spray
Drug: Midazolam Nasal Spray 0.9 mg/spray

First Posted Date: 2024-03-26

Last Posted Date: 2025-01-07

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 36

Registration Number: NCT06330584

Locations: 🇨🇭
Inselspital, Universitätsspital Bern, Bern, Switzerland
🇨🇭
Universitäres Zentrum für Palliative Care (UZP), Bern, Switzerland
🇨🇭
Zentrum für Palliative Care, Stadtspital Zürich, Zürich, Switzerland

and more 1 locations

Early Life Intervention in Pediatrics Supported by E-health - SMOKE

Not Applicable

Recruiting

Conditions: Asthma in Children
Behavior, Smoking
Life Style
Smoking Reduction
Non-Communicable Disease
Wheezing

Interventions: Behavioral: Life-Style app
Other: Sham Comparator

First Posted Date: 2024-03-15

Last Posted Date: 2024-05-16

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 160

Registration Number: NCT06311162

Locations: 🇨🇭
Department of Paediatrics, Inselspital, Bern University Hospital, Bern, Switzerland

Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer

Phase 2

Not yet recruiting

Conditions: Bile Duct Cancer

Interventions: Drug: Gemcitabin, Cisplatin and Durvalumab
Procedure: Biliary Radiofrequency Ablation
Procedure: Endoscopic Retrograde Cholangio-Pancreatography with stenting

First Posted Date: 2024-02-23

Last Posted Date: 2025-01-09

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 36

Registration Number: NCT06274879

Locations: 🇨🇭
Inselspital Bern University Hospital, Bern, Be, Switzerland

Molecular Imaging Study of Harmine/DMT: a Basic Research Approach

Phase 1

Completed

Conditions: Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine

Interventions: Drug: N,N-dimethyltryptamine (DMT) + harmine
Drug: Placebo

First Posted Date: 2024-02-09

Last Posted Date: 2025-03-19

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 17

Registration Number: NCT06252506

Locations: 🇨🇭
Department of Nuclear Medicine, Bern University Hospital, Bern, Switzerland
🇨🇭
Psychiatric University Hospital Zurich, Zurich, Switzerland

Longterm Functional Outcomes in Patients Undergoing Organ Preserving Treatment for Rectal Cancer With or Without Local Excision After Chemoradiotherapy

Recruiting

Conditions: Rectal Cancer

Interventions: Other: Local excision

First Posted Date: 2024-02-08

Last Posted Date: 2024-11-13

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 200

Registration Number: NCT06249672

Locations: 🇨🇭
Bern University Hospital, Inselspital, Bern, Switzerland

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy